Navigation Links
Schering-Plough Announces Presentation of Phase II Trial Results,for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual,Meeting of The American College of Cardiology/i2 Summit

KENILWORTH, N.J., March 12, 2007 /PRNewswire-FirstCall/ -- Schering-Plough Corporation announced today that results of the Phase II trial of its novel oral thrombin receptor antagonist (TRA) SCH 530348 will be presented at the 2007 annual Scientific Sessions of the of Cardiology (ACC.07)/Innovation in Intervention (i2) Summit, March 24-27 in New Orleans. The Phase II trial, referred to as the Thrombin Receptor Antagonist in Percutaneous Coronary Intervention (TRA-PCI) trial, has been accepted as a late-breaker presentation.

The trial was designed to evaluate the safety and tolerability of Schering-Plough's TRA coadminstered with standard of care antithrombotic therapy (including aspirin and clopidogrel) in patients undergoing percutaneous coronary intervention (PCI). A secondary objective was to assess whether patients treated with the compound had fewer cardiovascular events such as heart attack, need for urgent coronary revascularization, or death at 60 days compared with patients treated with the standard of care.

The Phase II trial, with an abstract titled Results of a Multinational, Randomized, Double-Blind, Placebo-Controlled Study of a Novel Thrombin Receptor Antagonist SCH 530348 in Percutaneous Coronary Intervention, will be presented by the TRA-PCI investigators.

About Schering-Plough Corporation

Schering-Plough is a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough's vision is to earn the trust of the physicians, patients and customers served by its approximately 33,500 people around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.sch
'"/>




Page: 1 2

Related medicine technology :

1. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
2. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study

Post Your Comments:
(Date:11/6/2009)... DIEGO, Nov. 6 California American... as "No Drugs Down the Drain" week for its San Die...ign sponsored by public and private agencies alike...cal pollution in our source water supplies. ,, ...mers are encouraged to drop off expired or unwante...
(Date:11/5/2009)... DIEGO, Nov. 5 Althea Technologie...ufacturing services for biopharmaceutical products...Development to the company,s platform of services,... James Matsuura, Director of Formulation Developme...ulation and analytical scientists, along with new ...
(Date:11/5/2009)...NA, Minn., Nov. 5 ARKRAY, Inc., th...f-monitoring systems, today announced that it has ...g Administration for its new GLUCOCARD Vital blood...d strip platform, which ARKRAY will make available...o be a significant complement to the existing GLUC...
Breaking Medicine Technology:California American Water Celebrates 'No Drugs Down the Drain' Week in San Diego 2Althea Technologies Adds Formulation Development to Its Integrated Offering of Contract Services 2ARKRAY, Inc. Receives FDA Clearance for New GLUCOCARD(R) Vital(TM) Blood Glucose Monitoring System 2Academic Opinion Leaders in the Field of Spine Surgery 26 Sacroiliac Joint Experts Attend SI BONEs National Summit on the Diagnosis of Sacroiliac Pat 57438 1Academic Opinion Leaders in the Field of Spine Surgery 26 Sacroiliac Joint Experts Attend SI BONEs National Summit on the Diagnosis of Sacroiliac Pat 57438 2Academic Opinion Leaders in the Field of Spine Surgery 26 Sacroiliac Joint Experts Attend SI BONEs National Summit on the Diagnosis of Sacroiliac Pat 57438 3Academic Opinion Leaders in the Field of Spine Surgery 26 Sacroiliac Joint Experts Attend SI BONEs National Summit on the Diagnosis of Sacroiliac Pat 57438 4Aethlon Medical Inc Announces Annual Meeting Results 14111 1Aethlon Medical Inc Announces Annual Meeting Results 14111 2Aethlon Medical Inc Announces Annual Meeting Results 14111 3Viral Genetics Lead Scientist Dr M Karen Newell Will Present at 11th Annual SoCalBio Investor and Partnership Conference 14106 1Viral Genetics Lead Scientist Dr M Karen Newell Will Present at 11th Annual SoCalBio Investor and Partnership Conference 14106 2
...ons of Body Consistent with Overall PASI ... ANTONIO, Feb. 4 Data from an integrated analysis...owed patients with moderate,to severe plaque psori...,consistently high level of skin clearance in each...upper extremities) as measured by the Psoriasis,Ar...
...copeia (Nasdaq:,PCOP), an innovator in the discove...utics, today announced that Dr. Leslie J. Browne, ...r a corporate presentation at the,BIO CEO & Invest...bruary,11-13, 2008, at The Waldorf-Astoria Hotel i...take place at 2:00 p.m. EST on Tuesday,February 12...
Other Medicine Technology:REMICADE-Treated Patients Experienced Rapid and Substantial Improvement in Psoriasis in Critical Regions of Body 2REMICADE-Treated Patients Experienced Rapid and Substantial Improvement in Psoriasis in Critical Regions of Body 3REMICADE-Treated Patients Experienced Rapid and Substantial Improvement in Psoriasis in Critical Regions of Body 4REMICADE-Treated Patients Experienced Rapid and Substantial Improvement in Psoriasis in Critical Regions of Body 5REMICADE-Treated Patients Experienced Rapid and Substantial Improvement in Psoriasis in Critical Regions of Body 6REMICADE-Treated Patients Experienced Rapid and Substantial Improvement in Psoriasis in Critical Regions of Body 7REMICADE-Treated Patients Experienced Rapid and Substantial Improvement in Psoriasis in Critical Regions of Body 8REMICADE-Treated Patients Experienced Rapid and Substantial Improvement in Psoriasis in Critical Regions of Body 9REMICADE-Treated Patients Experienced Rapid and Substantial Improvement in Psoriasis in Critical Regions of Body 10Pharmacopeia to Present at BIO CEO & Investor Conference 2008 2Pharmacopeia to Present at BIO CEO & Investor Conference 2008 3
(Date:11/8/2009)...etwork of Hispanic health advocates committed to a..., WASHINGTON, Nov. 7 ...they have heard the voice of America,s families by...t. Now the Senate must deliver, without delay, on ...d Dr. Jane L. Delgado, President and CEO of the Na...
(Date:11/8/2009)...ssage of H.R. 3961 to Secure the Stability of Medi.../ -- Statement Attributable to: J. James Rohack, M..., (Logo: http://www.newscom.com/cgi-bin/prnh/200... of the House health reform bill, which will help ...ans and calls for swift passage of H.R. 3961 to se...
(Date:11/8/2009)...hows Who Sides With Working Families vs. Insurance...ire-USNewswire/ -- On the heels of an historic lat... good, balanced health care reform bill, the Penns...ate,s U.S. representatives voted on HR 3962, the A...legislation, which passed Saturday evening by a vo...
(Date:11/7/2009)... Karen Ignagni, Presiden...P), released the following statement today on Hous...ly support comprehensive health care reform, and w... a complete overhaul of how health insurance is pr...coverage, elimination of pre-existing condition ex...
(Date:11/7/2009)...Newswire-USNewswire/ -- The American Medical Assoc...r of Health at the Family Violence Prevention Fund...y at its semi-annual policy-making meeting. The C...onor the AMA House of Delegates bestows on a non-p.../cgi-bin/prnh/20081209/AMALOGO ) ,, "Ms. Jame...
Breaking Medicine News(10 mins):Health News:National Alliance for Hispanic Health President and CEO Applauds House Action, Calls on Senate to Pass Health Reform in 2009 2Health News:AMA Hails House Passage of Health Reform Bill (H.R. 3962) 2Health News:Robert Brady (D-PA-1), Chaka Fattah (D-PA-2), Kathy Dahlkemper (D-PA-3), Joe Sestak (D-PA-7), Patrick Murphy (D-PA-8), Christopher Carney (D-PA-10), John Murtha (D-PA-12), Paul Kanjorski (D-PA-11), Allyson Schwartz (D-PA-13), Mike Doyle (D-PA-14) Ge 2Health News:AHIP Statement on House Passage of H.R. 3962 2Health News:AMA Honors Family Violence Prevention Expert 2
...GTON Children who suffer traumatic brain injuries...chological problems, highlighting the need for car...published by the American Psychological Associatio...The researchers found that severe TBI can cause ma...
... Three military veterans with ALS a... from ALS (amyotrophic lateral sclerosis) have pla...ceremony sponsored by The ALS Association. , ...rom ALS (amyotrophic lateral sclerosis) have place...
... On May 12, Physicians for Human Ri...an 16 countries will hold a Global Day of Action c...es and immediately release Kamiar and Arash Alaei....there is still continuing vigilance over the unjus...
...ES, May 11 Today, (RED) and Live Nation (... an innovative slate of 26 live concerts in th...he ultimate goal of eliminating AIDS in Africa. To... and The All-American Rejects will turn o...
...Positioned to Review Medical Technology , , WASHI...me to Washington, D.C., to share their stories abo...ve their lives in advance of a May 12 U.S. House o...tion,s (FDA) preemption authority. , , "Without ...
...ment Algorithms Data from Decision Resources Allow...low Models that Better Forecast Market Share , , ... the world,s leading research and advisory firms f...nced by physician perception that the former is mo...
Other Medicine News:Health News:Traumatic brain injury haunts children for years with variety of functional problems: Two studies 2Health News:Traumatic brain injury haunts children for years with variety of functional problems: Two studies 3Health News:Traumatic brain injury haunts children for years with variety of functional problems: Two studies 4Health News:Military Veterans Struck Down by Lou Gehrig's Disease Honored on Mother's Day by The ALS Association with Wreath Laying Ceremony at Arlington National Cemetery 2Health News:Saberi Release Highlights Case of Imprisoned Iranian AIDS Doctors 2Health News:Saberi Release Highlights Case of Imprisoned Iranian AIDS Doctors 3Health News:(RED)(TM) and Live Nation Announce (RED)NIGHTS, the Concert Series to Combat AIDS in Africa 2Health News:(RED)(TM) and Live Nation Announce (RED)NIGHTS, the Concert Series to Combat AIDS in Africa 3Health News:(RED)(TM) and Live Nation Announce (RED)NIGHTS, the Concert Series to Combat AIDS in Africa 4Health News:(RED)(TM) and Live Nation Announce (RED)NIGHTS, the Concert Series to Combat AIDS in Africa 5Health News:Patients Call for Continued FDA Preemption Authority 2Health News:Patients Call for Continued FDA Preemption Authority 3Health News:Patients Call for Continued FDA Preemption Authority 4Health News:More Patients Receive Diovan As A First- Or Second-Line Therapy Compared With Cozaar or Avapro 2Health News:More Patients Receive Diovan As A First- Or Second-Line Therapy Compared With Cozaar or Avapro 3
Bishop Harmon Style Tissue Forceps
Bishop Harmon Forceps
Tissue Forceps (Bishop-Harmon)
Capsulorhexis Forceps Angled
Medicine Products: